

		EMLc	ATC codes: L03AA02
Indication	Acquired neutropaenia	ICD11 code: 4B00.01	
INN	Filgrastim		
Medicine type	Biological agent		
List type	Complementary (EML) (EMLc)		
Additional notes	Including quality-assured biosimilars.		
Formulations	Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe ; 300 µg per 0.5 mL in prefilled syringe ; 480 µg per 0.8 mL in prefilled syringe ; 300 µg per mL in 1 mL vial ; 480 µg per 1.6 mL in 1.6 mL vial		
EML status history	First added in 2015 (TRS 994)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents.</a> 		
Tags	<span>Cancer</span> <span>Biological</span>		
Wikipedia	<a href="#">Filgrastim</a> 		
DrugBank	<a href="#">Filgrastim</a> 		

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, filgrastim, a granulocyte colony stimulating factor, was added to the complementary list of the EML and EMLc for use in the following indications: - primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy; - secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy; - to facilitate administration of dose dense chemotherapy regimens. The relevant extract from TRS994 regarding the Expert Committee's consideration of G-CSF is attached.

[Expert Committee report](#) 

